白蛋白结合型紫杉醇单药作为三线及以上方案治疗晚期非小细胞肺癌的临床研究  

Clinical study of nanoparticle albumin-bound paclitaxel (single-agent regimen) as third-and further-line therapy in advanced non-small cell lung cancer patients

作　　者：蒋侃[1] 黄诚[1] 吴标[1] 林根[1] 张晶[1] JIANG Kan HUANG Cheng WU Biao LIN Gen ZHANG Jing(Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fujian Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, 350014)

机构地区：[1]福建医科大学教学医院福建省肿瘤医院内科,福建福州350014

出　　处：《分子诊断与治疗杂志》2017年第2期112-116,共5页Journal of Molecular Diagnostics and Therapy

基　　金：福建省青年课题基金(2015-1-14)

摘　　要：目的观察白蛋白结合型紫杉醇单药三线及以上治疗晚期非小细胞肺癌的近期疗效及不良反应。方法选取2013年10月至2015年3月在福建省肿瘤医院已接受过二线治疗的晚期非小细胞肺癌患者46例,予以白蛋白结合型紫杉醇260 mg/m2D1,每21天为一周期,每个周期复查CT评价疗效,观察其疗效及不良反应。结果完全缓解(CR)0例,部分缓解(PR)6例,疾病稳定(SD)26例,疾病进展(PD)14例,客观缓解率(ORR)13%,疾病控制率(DCR)70%,中位无进展生存期(PFS)4.7月,主要不良反应为血液学毒性、肝功能损害,外周神经毒性,无毒性相关死亡病例。结论白蛋白结合型紫杉醇用于三线及以上治疗晚期非小细胞肺癌,ORR及DCR高,不良反应可以耐受。Objective To observe the efficacy and toxicity of nanoparticle albumin-bound paclitaxel（Nab-P） as third-and further-line chemotherapeutic approach for advanced non-small cell lung cancer（NSCLC） patients. Methods A total of 46 advanced NSCLC patients that have received second-line therapy were recruited from Fujian Province Cancer Hospital from October 2013 to March 2015. Nab-P 260 mg/m^2 D1 was applied as a single-agent regimen for third-and further-line chemotherapy by intravenous administration for a 21 day cycle. Efficacy was estimated by imaging every cycle. Results Out of the 46 total patients, 6patients was achieved partial relief（PR）, 26 patients were disease stable（SD）, and 14 patients had disease progression（PD）. The objective response rate（ORR） was 13%. The disease control rate（DCR） was 70%. The median progression free survival（PFS） was 4.7 months. The most commonly seen adverse events（AEs） were myelosuppression, liver dysfunction, and peripheral neurotoxicity. There were no treatment-related deaths.Conclusion Using Nab-P as a signle-agent regimen for third-and further-line chemotherapy in advanced NSCLC patients was both effective and safe. The adverse events were well tolerated.

关 键 词：白蛋白结合型紫杉醇 多线化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]